Indication

Basal cell carcinoma of skin

Basal cell carcinoma of skin is a common, slow-growing cutaneous malignancy arising from the pluripotential epithelial cells within the basal layer of the epidermis and hair follicles. Read more about Basal cell carcinoma of skin

5 drugs 5 manufacturers

Advertisement

Drugs that treat it

Common Basal cell carcinoma of skin therapies.

Showing 1–5 of 5 drugs

LIBTAYO (cemiplimab-rwlc)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·BASAL CELL CARCINOMA OF SKIN·+3
Regeneron Pharmaceuticals, Inc.
Sponsored
Filter & compare in the drug finder →Opens the drug finder with Basal cell carcinoma of skin preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Basal cell carcinoma of skin.

Basal cell carcinoma of skin is a common, slow-growing cutaneous malignancy arising from the pluripotential epithelial cells within the basal layer of the epidermis and hair follicles.

It predominantly affects the integumentary system of older adults and fair-skinned individuals, most frequently presenting in chronologically sun-damaged anatomical areas such as the head, neck, and extremities.

Pathophysiologically driven by cumulative ultraviolet radiation exposure and aberrant Hedgehog signaling pathway activation, lesions classically manifest as pearly, translucent papules or plaques with telangiectasias, rolled borders, or central ulceration.

Although distant metastasis is rare, the condition can cause substantial local tissue invasion and destruction if left untreated.

Personalize your experience

Follow Basal cell carcinoma of skin and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it